Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy M Clay

Showing results (51-60 of 71) with videos related to

Pageof 8
Sort By:
The Journal of Clinical Investigation|August 4, 2010
An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancerMichael A Morse, Amy C Hobeika, Takuya Osada, et al.
Breast Cancer Research : BCR|August 11, 2018
Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancersTakuya Osada, Zachary C Hartman, Junping Wei, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 16, 2009
Priming and activation of human ovarian and breast cancer-specific CD8+ T cells by polyvalent Listeria monocytogenes-based vaccinesGomathinayagam Sinnathamby, Peter Lauer, Jennifer Zerfass, et al.
Cancer Immunology, Immunotherapy : CII|April 11, 2012
Co-delivery of antigen and IL-12 by Venezuelan equine encephalitis virus replicon particles enhances antigen-specific immune responses and antitumor effectsTakuya Osada, Peter Berglund, Michael A Morse, et al.
Journal of Translational Medicine|February 23, 2005
A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancerMichael A Morse, Jennifer Garst, Takuya Osada, et al.
Journal of Translational Medicine|February 14, 2012
Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected]Erika Hamilton, Kimberly Blackwell, Amy C Hobeika, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2009
Induction of Wilms' tumor protein (WT1)-specific antitumor immunity using a truncated WT1-expressing adenovirus vaccineTakuya Osada, Christopher Y Woo, Matthew McKinney, et al.
Vaccine|October 18, 2011
Increasing vaccine potency through exosome antigen targetingZachary C Hartman, Junping Wei, Oliver K Glass, et al.
Journal of the National Cancer Institute|September 21, 2010
CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancerXinhui Wang, Takuya Osada, Yangyang Wang, et al.
Journal of Immunological Methods|December 13, 2005
Maximizing the retention of antigen specific lymphocyte function after cryopreservationMary L Disis, Corazon dela Rosa, Vivian Goodell, et al.
Pageof 8

Showing results (51-60 of 71) with videos related to

Sort By:
Pageof 8
The Journal of Clinical Investigation|August 4, 2010
An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancerMichael A Morse, Amy C Hobeika, Takuya Osada, et al.
Breast Cancer Research : BCR|August 11, 2018
Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancersTakuya Osada, Zachary C Hartman, Junping Wei, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 16, 2009
Priming and activation of human ovarian and breast cancer-specific CD8+ T cells by polyvalent Listeria monocytogenes-based vaccinesGomathinayagam Sinnathamby, Peter Lauer, Jennifer Zerfass, et al.
Cancer Immunology, Immunotherapy : CII|April 11, 2012
Co-delivery of antigen and IL-12 by Venezuelan equine encephalitis virus replicon particles enhances antigen-specific immune responses and antitumor effectsTakuya Osada, Peter Berglund, Michael A Morse, et al.
Journal of Translational Medicine|February 23, 2005
A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancerMichael A Morse, Jennifer Garst, Takuya Osada, et al.
Journal of Translational Medicine|February 14, 2012
Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected]Erika Hamilton, Kimberly Blackwell, Amy C Hobeika, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2009
Induction of Wilms' tumor protein (WT1)-specific antitumor immunity using a truncated WT1-expressing adenovirus vaccineTakuya Osada, Christopher Y Woo, Matthew McKinney, et al.
Vaccine|October 18, 2011
Increasing vaccine potency through exosome antigen targetingZachary C Hartman, Junping Wei, Oliver K Glass, et al.
Journal of the National Cancer Institute|September 21, 2010
CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancerXinhui Wang, Takuya Osada, Yangyang Wang, et al.
Journal of Immunological Methods|December 13, 2005
Maximizing the retention of antigen specific lymphocyte function after cryopreservationMary L Disis, Corazon dela Rosa, Vivian Goodell, et al.
Pageof 8